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Pancreatic sphincterotomy to manage intraductal papillary
mucinous neoplasm-related recurrent pancreatitis: are we ready
for a controlled trial?
We read with interest the study by Gon-
zalez et al. reporting a multicenter
French experience with pancreatic
sphincterotomy (PS) as treatment for in-
traductal papillary mucinous neoplasm
(IPMN)-associated symptoms [1]. In
2017, we published a similar article on
this topic including 16 patients treated
in a single center [2]. In the two studies,
outcomes were defined in a similar man-
ner: a complete response was achieved
when no pancreatitis episodes were ob-
served during follow-up, whereas a par-
tial response was defined as a reduction
>50% of pancreatitis attacks. However,
quite different populations were includ-
ed. In the study by Gonzalez et al. [1],
only branch-duct IPMN (BD-IPMN) with-
out worrisome features were evaluated,
whereas we also included patients with
main-duct IPMN unfit for surgery due to
comorbidities, or patients who refused
surgery. Moreover, Gonzalez et al. in-
cluded patients with “post-prandial ab-
dominal pain (typical characteristics and
no associated functional disease)” [1].
However, PS should not be performed at
all for “pancreatic pain” in the light of
EPISOD trial results [3]. In our study, we
included only patients with recurrent
pancreatitis (RP) with the rigorous exclu-
sion of those with other concomitant
causes of RP [2]. It is not clear if other
causes of RP were excluded in Gonzalez
et al. [1]. Indeed, in 33% of their cases, a
biliary sphincterotomy was also per-
formed due to associated biliary dilata-
tion with cholestasis or cholangitis. This
selection bias could have affected their
results with regard to the clinical success
of PS.
In both studies, PS was performed at
major or minor papilla depending on the
anatomy of the ductal system. However,
technical differences between the two
studies should be highlighted. First, a
pancreatic stent was deployed in 33% of
cases in Gonzalez et al. [1], whereas in
our study, we did not place any stent fol-
lowing an internal policy based on the
risk of stent occlusion related to the mu-
cus passage [2]. Second, a dual sphinc-
terotomy (biliary and pancreatic) was
performed in 33% of the cases in the
French study but in none of our cases
[1, 2].
Despite the aforementioned differen-
ces in the studies’ methodology and in
technical practice, Gonzalez et al. [1]
have reproduced our results published
in 2017 [2]. Technical success was 100%
in both studies. The clinical success was
comparable (complete response 71% vs
69% and partial response 10% vs 19% in
Gonzalez et al. and in our study, respec-
tively) with an overall response rate of
approximately 80% [1, 2]. However, the
great limitation of the absence of control
groups must be mentioned.
The procedure was safe in both ex-
periences. Four (19%) and one (6%)
ERCP-related mild pancreatitis were ob-
served in Gonzalez et al. [1] and in Ber-
nardoni et al. [2], respectively. Interest-
ingly, in both studies, none of the BD-
IPMN patients developed high risk stig-
mata or adenocarcinoma during a long
follow-up [1, 2].
Pancreatic IPMNs are often diag-
nosed in elderly patients affected by co-
morbidities who are likely to die with
the cyst rather than die because of the
cyst [4]. Moreover, looking at younger
people, the incidence of cancer in BD-
IPMNs is rare [5]. On the other hand,
pancreatic surgery is burdened by mor-
tality and morbidity. Therefore, an ef-
fective and safe tool to treat RP in this
setting of patients is a worthwhile goal.
The study by Gonzalez et al. has
strengthened the evidence reported in
our article. Now we need a prospective
multicenter controlled trial with a rigor-
ous selection of patients and standard-
ized technique to definitively assess the
role of PS in the management of IPMN-
related pancreatitis.
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